Novo Nordisk Stock in 2025: Time to Buy, Sell, or Hold?

Pharma giant Novo Nordisk faces a make-or-break moment—will its diabetes and obesity drugs keep printing cash, or is the hype overbought?

The Bull Case: Ozempic Can't Miss

Demand for GLP-1 therapies isn't slowing down. With 500M+ obese adults globally and insurers finally loosening purse strings, Novo's pipeline looks like a license to mint money.

The Bear Trap: Patent Cliffs Ahead

Generic competitors are circling like vultures. By 2028, key patents expire—can Novo innovate fast enough to stay ahead? Or will it become another 'blockbuster-to-bust' pharma cautionary tale?

The Bottom Line

At 35x earnings, Novo's priced for perfection. One pipeline setback could trigger a haircut worse than a hedge fund's crypto portfolio. But for now, the trend remains your pharma friend.